Evidence map›Paper›PMID 33007077›Full record

GuidelineBlood advances2020

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Thomas L Ortel, Ignacio Neumann, Walter Ageno, Rebecca Beyth, Nathan P Clark, Adam Cuker, Barbara A Hutten, Michael R Jaff, Veena Manja, Sam Schulman and 12 more

Registry-linked trialOpen access · goldAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04981327 (The API-CALF Study), which is not on this map. Cited by 679 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
679citing papers in PubMed, 13 pooled it
84.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04981327 phase3not yet recruitingnot on this mapstarted 2022, after this paper: background citation

The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis

TypeinterventionalSponsorUniversity Hospital, GenevaRan2022 to 2027Enrolled1,300ConditionsDeep Vein ThrombosisArmsApixaban 2.5 MG Oral Tablet [ELIQUIS]
3 · Its place in the literature

Who cites it

679 citing papers in PubMed, 13 syntheses or guidelines pooled it, 1,355 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Efficacy of Atorvastatin Against Venous Thromboembolism After Total Hip Arthroplasty.Journal of musculoskeletal & neuronal interactions · 2025
    Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

619 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 14 institutions in 7 countries.

Thomas L OrtelDivision of Hematology, Department of Medicine, Duke University, Durham NC.
Ignacio NeumannPontificia Universidad Catolica de Chile, Santiago, Chile.
Walter AgenoDepartment of Medicine and Surgery, University of Insurbria, Varese, Italy.
Rebecca BeythDivision of General Internal Medicine, Department of Medicine, University of Florida, Gainesville, FL.
Nathan P ClarkClinical Pharmacy Anticoagulation Service, Kaiser Permanente, Aurora, CO.
Adam CukerDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Barbara A HuttenDepartment of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Michael R JaffHarvard Medical School, Boston, MA.
Veena ManjaUniversity of California Davis, Sacramento, CA.
Sam SchulmanDepartment of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada.
Caitlin ThurstonMay-Thurner Syndrome Resource Network.
Suresh VedanthamDivision of Diagnostic Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO.
Peter VerhammeKU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Daniel M WittDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT.
Ivan D FlorezDepartment of Pediatrics, University of Antioquia, Medellin, Colombia.
Ariel IzcovichInternal Medicine Department, German Hospital, Buenos Aires, Argentina; and.
Robby NieuwlaatDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Stephanie RossDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Holger J SchünemannDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Wojtek WierciochDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Yuan ZhangDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Yuqing ZhangDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Impact · CAAmsterdam University Medical Centers · NLDuke University · USHarvard University · USKaiser Permanente · USKU Leuven · BEPontificia Universidad Católica de Chile · CLSechenov University · RUUniversidad de Antioquia · COUniversity of Florida · USUniversity of Pennsylvania · USUniversity of Utah · USVA Northern California Health Care System · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVenous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually.

objectiveThese evidence-based guidelines from the American Society of Hematology (ASH) intend to support patients, clinicians, and others in decisions about treatment of VTE.

methodsASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and adult patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment.

resultsThe panel agreed on 28 recommendations for the initial management of VTE, primary treatment, secondary prevention, and treatment of recurrent VTE events.

conclusionsStrong recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range of 2.0 to 3.0 over a lower INR range for patients with VTE who use a vitamin K antagonist (VKA) for secondary prevention, and use of indefinite anticoagulation for patients with recurrent unprovoked VTE. Conditional recommendations include the preference for home treatment over hospital-based treatment for uncomplicated DVT and PE at low risk for complications and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.

Indexed as

HematologyPulmonary EmbolismVenous ThromboembolismVenous ThrombosisEvidence-Based MedicineHumansUnited States

Identifiers

PMID33007077
PMCPMC7556153
OpenAlexW3090209681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.